The desire to increase life quality and expectancy is what drives the top anti-aging stocks in the life science space as they pursue technologies and therapies aimed at slowing the aging process and preserving health. Age-related diseases are a main focus of this sector, including cancers, cardiovascular diseases, Alzheimer’s disease, Parkinson’s disease and osteoarthritis.
For those considering which anti-aging stocks to invest in, below is a brief overview of five NASDAQ-listed stocks with market caps between US$50 million and US$500 million. NYSE companies were considered but didn’t make the cut.
All company figures were current as of August 9, 2024.
Market cap: US$477.225 million
California-based GRAIL is focused on the area of precision oncology through early cancer detection technology. The healthcare company has developed a methylation-based multi-cancer early detection platform known as Galleri. It incorporates next-generation sequencing and large-scale clinical studies with machine learning, software and automation to detect and identify multiple types of cancer and monitor for reoccurrence.
Market cap: US$394.35 million
Clinical-stage Verve Therapeutics is developing single-course gene-editing treatments for lowering LDL cholesterol (the “bad” cholesterol), which is closely linked to atherosclerotic cardiovascular diseases — the leading cause of death globally.
“Our Heart-2 Phase 1b clinical trial of VERVE-102 continues to progress as we focus on enrolling patients and expanding the trial’s geographic footprint, highlighted by our recent regulatory clearance in Australia,” stated Verve co-founder and CEO Sekar Kathiresan.
“We look forward to providing initial data from the Heart-2 clinical trial in the first half of 2025. In addition, we are on track to initiate the Phase 1b clinical trial for our ANGPTL3 product candidate, VERVE-201, in the second half of this year, and we continue to advance our early-stage programs, including one targeting the LPA gene.”
Market cap: US$372.474 million
Headquartered in Boston, Massachusetts, Anika Therapeutics is focused on advancements in early intervention orthopedic care and joint preservation. The company is developing minimally invasive products that leverage its expertise in hyaluronic acid and implants to restore active living for patients. Its target areas include age-related and injury-related fields such as osteoarthritis pain management, regenerative solutions, sports medicine and arthrosurface joint implants.
“OA Pain Management remains a strong, foundational element of our business and represents a key aspect of total company profitability,” Cheryl R. Blanchard, Anika Therapeutics president and CEO, stated in the release.
Market cap: US$374.22 million
Pennsylvania’s Ocugen is working to bring to market gene and cell therapies for the treatment of ocular and orthopedic conditions.
It is also developing OCU410, a modifier gene therapy targeting geographic atrophy, an advanced stage of dry age-related macular degeneration. It leverages a nuclear hormone receptor gene called RORA and is a single sub-retinal injection that has the potential to be a one-time therapy for life. According to the company, current treatment options require 6 to 12 doses per year.
Another therapy in Ocugen’s pipeline is NEOCART, a regenerative cell therapy for the treatment of articular cartilage defects in the knee that can lead to osteoarthritis. The company intends to launch the Phase 3 trial for NEOCART once it can secure adequate funding.
Market cap: US$348.164 million
This is an updated version of an article originally published by the Investing News Network in 2017.
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
Leave a Reply